Views & Analysis | Perspectives on pharma industry issues

Market Access

Two business hands outstretched, one weighing cash, the other drugs, for balance

What the revised 340B rebate pilot programme means for pharm...

While the scope of the revised pilot is limited, it may be a harbinger for a broader policy shift.

Digital

IQVIA Technologies sponsored podcast, with Updesh Dosanjh

AI-enabled pharmacovigilance, with Updesh Dosanjh

Updesh Dosanjh, IQVIA commercialisation lead for safety technology, discusses how and why the role of AI in pharmacovigilance is changing.

Digital

Two female silhouettes in a city office overlook the urban landscape below

How female leadership can benefit industry

Day One Strategy’s founding partners Abigail Stuart and Hannah Mann share the benefits female leadership can bring to industry.

Patients

Maintenance: The underexamined half of the GLP-1 story

GLP-1 treatments have historically had an exit problem, as appetite suppression stops when the medication stops.

Oncology

pharmaphorum podcast Episode 276, Irina Babina, Concr

Getting predictive technologies to patients, with Concr

Dr Irina Babina, CEO of oncology R&D platform Concr, discusses how current regulatory frameworks were built for static diagnostics.

Articles

Pharma gets social: China – pharma’s social media frontier

In this month’s ‘Pharma gets social’ article, Daniel Ghinn explores the digital and social media channels in China, to coincide with our emerging markets focus. While social media is still considered by some in pharmaceutical marketing to be a new frontier anywhere in the world, the emerging market of China...

Articles

Spotlight on...diabetes

We interview Prof Carel le Roux about diabetes, including the early symptoms and the latest developments in treatments available for patients. Did you know that by the year 2025, an estimated four million people in the UK will have diabetes? Our latest “Spotlight on...” article focuses on Type 1 and Type 2 diabetes...

Articles

Aris’ musings: what makes a pharma innovator?

In place of Tunnah’s musings this month, Rebecca Aris offers her thoughts on why it’s high time that we open our eyes to the innovation that surrounds us within the pharmaceutical industry and lists the top ten pharma innovators as voted by our audience. Definitions of innovation in pharma differ as we all have a different idea of what true innovation is. Inadequate innovation has…

Sales & Marketing

Accelerating growth through strategic investment in healthca...

CEVA FORPATIENTS at Rockingham, UK will offer the healthcare supply chain a new, sustainably designed multi-user site.

Sales & Marketing

The patient communication crisis pharma can no longer ignore

Industry's significant investments in patient engagement are only effective if patients trust the communication enough to answer in the first place.

Digital

AI-enabled pharmacovigilance, with Updesh Dosanjh

Updesh Dosanjh, IQVIA commercialisation lead for safety technology, discusses how and why the role of AI in pharmacovigilance is changing.

Digital

How female leadership can benefit industry

Day One Strategy’s founding partners Abigail Stuart and Hannah Mann share the benefits female leadership can bring to industry.

Market Access

What the revised 340B rebate pilot programme means for pharm...

While the scope of the revised pilot is limited, it may be a harbinger for a broader policy shift.

Market Access

$100 notes in pill bottle on aquamarine background with spilled pills

How new PBM transparency rules will alter drug pricing

The complex drug pricing ecosystem means all stakeholders are scrambling to understand how the new regulations and PBMs’ adjustments will impact them.